These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 29446164)

  • 21. Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid, likely triggered by scabies, in a hemodialysis patient with human leukocyte antigen-DQB1*03:01.
    Hibi A; Kasahara Y; Ishihara Y; Hata K; Hosokawa N; Nakagawa T
    CEN Case Rep; 2020 Aug; 9(3):189-194. PubMed ID: 31993957
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Defining dipeptidyl peptidase-4 inhibitors-related bullous pemphigoid: A single-centre retrospective study.
    Nieto-Benito LM; Bergón-Sendín M; Pulido-Pérez A; Rosell-Díaz ÁM; Parra-Blanco V; Suárez-Fernández R
    Exp Dermatol; 2021 Sep; 30(9):1345-1351. PubMed ID: 34028898
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid.
    Tasanen K; Varpuluoma O; Nishie W
    Front Immunol; 2019; 10():1238. PubMed ID: 31275298
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors. A case series and analysis of cases reported in the Spanish pharmacovigilance database.
    Reolid A; Muñoz-Aceituno E; Rodríguez-Jiménez P; González-Rojano E; Llamas-Velasco M; Fraga J; Daudén E
    Int J Dermatol; 2020 Feb; 59(2):197-206. PubMed ID: 31605541
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: Retrospective multicenter case-control study from France and Switzerland.
    Benzaquen M; Borradori L; Berbis P; Cazzaniga S; Valero R; Richard MA; Feldmeyer L
    J Am Acad Dermatol; 2018 Jun; 78(6):1090-1096. PubMed ID: 29274348
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dipeptidyl peptidase-4 inhibitors-associated bullous pemphigoid: A retrospective study of 168 pemphigoid and 9,304 diabetes mellitus patients.
    Kawaguchi Y; Shimauchi R; Nishibori N; Kawashima K; Oshitani S; Fujiya A; Shibata T; Ohashi N; Izumi K; Nishie W; Shimizu H; Arima H; Sobajima H
    J Diabetes Investig; 2019 Mar; 10(2):392-398. PubMed ID: 29920976
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bullous pemphigoid with dipeptidyl peptidase-4 inhibitors: Clinical features and pathophysiology.
    Murakami T; Yabe D; Inagaki N
    J Diabetes Investig; 2019 Sep; 10(5):1168-1170. PubMed ID: 30989811
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association between dipeptidyl peptidase-4 inhibitors and risk of bullous pemphigoid in patients with type 2 diabetes: A population-based cohort study.
    Wu CY; Wu CY; Li CP; Chou YJ; Lin YH; Chang YT
    Diabetes Res Clin Pract; 2021 Jan; 171():108546. PubMed ID: 33232759
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of the Clinical Characteristics of Dipeptidyl Peptidase-4 Inhibitor-Induced Bullous Pemphigoid.
    Sun L; Wang C; Wu C; Zhou Y; Wang C
    Ann Pharmacother; 2022 Feb; 56(2):205-212. PubMed ID: 34105395
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Three Cases of Bullous Pemphigoid Associated with Dipeptidyl Peptidase-4 Inhibitors - One due to Linagliptin.
    Mendonça FM; Martín-Gutierrez FJ; Ríos-Martín JJ; Camacho-Martinez F
    Dermatology; 2016; 232(2):249-53. PubMed ID: 26820308
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The association of dipeptidyl peptidase IV inhibitors and other risk factors with bullous pemphigoid in patients with type 2 diabetes mellitus: A retrospective cohort study.
    Guo JY; Chen HH; Yang YC; Wu PY; Chang MP; Chen CC
    J Diabetes Complications; 2020 Mar; 34(3):107515. PubMed ID: 31932172
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enzyme-linked immunosorbent assay in autoimmune blistering diseases: preliminary experience of the Dermatology Department of Cagliari.
    Atzori L; Deidda S; Aste N
    G Ital Dermatol Venereol; 2008 Feb; 143(1):1-8. PubMed ID: 18833046
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin.
    Skandalis K; Spirova M; Gaitanis G; Tsartsarakis A; Bassukas ID
    J Eur Acad Dermatol Venereol; 2012 Feb; 26(2):249-53. PubMed ID: 21466592
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Cross-Sectional Study Comparing the Prevalence of Bullous Pemphigoid Autoantibodies in 275 Cases of Type II Diabetes Mellitus Treated With or Without Dipeptidyl Peptidase-IV Inhibitors.
    Izumi K; Nishie W; Beniko M; Shimizu H
    Front Immunol; 2019; 10():1439. PubMed ID: 31297116
    [No Abstract]   [Full Text] [Related]  

  • 35. Gliptin Accountability in Mucous Membrane Pemphigoid Induction in 24 Out of 313 Patients.
    Gaudin O; Seta V; Alexandre M; Bohelay G; Aucouturier F; Mignot-Grootenboer S; Ingen-Housz-Oro S; Bernardeschi C; Schneider P; Mellottee B; Caux F; Prost-Squarcioni C
    Front Immunol; 2018; 9():1030. PubMed ID: 29881377
    [TBL] [Abstract][Full Text] [Related]  

  • 36. From Molecular Insights to Clinical Perspectives in Drug-Associated Bullous Pemphigoid.
    de Nicolas-Ruanes B; Ballester-Martinez A; Garcia-Mouronte E; Berna-Rico E; Azcarraga-Llobet C; Fernandez-Guarino M
    Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069109
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitor - A case report.
    Karthik S; Joseph PE; Babu T
    J Postgrad Med; 2019; 65(4):244-246. PubMed ID: 31535624
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The association between clinical and laboratory findings of bullous pemphigoid and dipeptidyl peptidase-4 inhibitors in the elderly: a retrospective study.
    Bukvić Mokos Z; Petković M; Balić A; Marinović B
    Croat Med J; 2020 Apr; 61(2):93-99. PubMed ID: 32378375
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical characteristics of bullous pemphigoid in elderly patients with type 2 diabetes mellitus: The association with the use of dipeptidyl peptidase-4 inhibitors].
    Kodera R; Chiba Y; Tamura Y; Miyazawa R; Tanei R; Mori S; Ito H; Araki A
    Nihon Ronen Igakkai Zasshi; 2019; 56(1):43-50. PubMed ID: 30760682
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detection and characterization of IgG, IgE, and IgA autoantibodies in patients with bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors.
    Fania L; Salemme A; Provini A; Pagnanelli G; Collina MC; Abeni D; Didona B; Di Zenzo G; Mazzanti C
    J Am Acad Dermatol; 2018 Mar; 78(3):592-595. PubMed ID: 28987492
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.